Phase II clinical trial - Appareil Digestif

IMMUNO-BIL (D48-1 PRODIGE 57)
Appareil Digestif
Ouvert depuis le: 07.19.2019
Site: Saint-Cloud
Public cible
Adulte
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Description de l'essai

IMMUNO-BIL is a non-comparative randomized 1:1 phase II study. This study will assess the efficacy and safety of the combination of durvalumab plus tremelimumab with or without weekly paclitaxel in patients with advanced BTC after failure of platinum-based chemotherapy.